The most common types of cancer treated in oncology include lung cancer, breast cancer, colorectal cancer, prostate cancer, and several blood cancers such as leukemia and lymphoma. These cancers account for the majority of new diagnoses globally each year. Understanding how they are classified, detected, and researched is essential for scientists and laboratory professionals working in oncology-related fields.
Which cancers are diagnosed most frequently worldwide?
The cancers diagnosed most frequently worldwide are lung cancer, breast cancer, colorectal cancer, prostate cancer, and stomach cancer. Together, these five cancer types represent a significant proportion of all new cancer cases identified annually. Skin cancers, including melanoma, are also among the most prevalent when non-melanoma variants are included in global counts.
Lung cancer consistently ranks among the leading causes of cancer-related mortality worldwide, largely due to late-stage detection. Breast cancer is the most frequently diagnosed cancer overall when both sexes are considered together. Colorectal cancer affects the colon and rectum and is particularly prevalent in high-income regions, where dietary and lifestyle factors are believed to contribute to incidence rates.
In the Benelux region, cancer incidence patterns broadly mirror these global trends, with colorectal, breast, lung, and prostate cancers appearing prominently in national health registries. This makes these cancer types a central focus for research institutions, biotech companies, and pharmaceutical firms operating in Belgium, the Netherlands, and Luxembourg.
How does oncology classify and categorize different cancer types?
Oncology classifies cancers primarily by their tissue of origin, meaning the type of cell from which the cancer arises. The two broadest categories are solid tumors, which form in organs and tissues, and hematological cancers, which originate in blood-forming cells. Within these categories, cancers are further classified by histological subtype, molecular profile, and stage of progression.
The main classification groups include:
- Carcinomas: Cancers arising from epithelial cells, covering the majority of solid tumors, including lung, breast, colorectal, and prostate cancers
- Sarcomas: Cancers originating in connective tissues such as bone, muscle, and fat
- Lymphomas: Cancers of the lymphatic system, including Hodgkin and non-Hodgkin lymphoma
- Leukemias: Cancers of blood-forming tissues, primarily affecting the bone marrow and blood
- Central nervous system tumors: Cancers originating in brain or spinal cord tissue
Modern oncology increasingly layers molecular and genetic classification on top of tissue-based categories. Identifying specific gene mutations, receptor expression, or protein markers allows researchers to group cancers by their biological behavior rather than anatomical location alone. This approach has become foundational to precision oncology research.
What are the most common solid tumor cancers treated in oncology?
The most commonly treated solid tumor cancers in oncology are lung cancer, breast cancer, colorectal cancer, prostate cancer, and pancreatic cancer. These tumors form discrete masses within organs or tissues and are typically diagnosed through imaging, biopsy, and molecular analysis. Their high incidence makes them a primary focus of oncology research worldwide.
Lung cancer is subdivided into non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), with NSCLC representing the large majority of cases. Research into its molecular drivers, including specific receptor mutations, has opened significant avenues for targeted therapy investigation.
Breast cancer is among the most molecularly diverse solid tumors, with subtypes defined by hormone receptor status and protein expression profiles. This diversity makes it a rich area for biomarker research and assay development in laboratory settings.
Colorectal cancer is notable for its strong association with identifiable genetic risk factors, making it a model system for hereditary cancer research. Prostate cancer, while often slow-growing, presents complex challenges in distinguishing aggressive from indolent forms, driving demand for sensitive detection and monitoring tools.
What blood cancers are most commonly treated in oncology?
The most commonly treated blood cancers in oncology are leukemia, lymphoma, and multiple myeloma. These hematological malignancies originate in blood-forming cells and affect the bone marrow, lymph nodes, and immune system. Unlike solid tumors, they do not typically form a single localized mass, which shapes how they are studied and modeled in research settings.
Leukemia is characterized by the overproduction of abnormal white blood cells and is categorized into four main types based on cell lineage and progression speed: acute lymphoblastic, acute myeloid, chronic lymphocytic, and chronic myeloid leukemia. Each subtype has distinct molecular characteristics that are actively investigated in research laboratories.
Lymphoma, including both Hodgkin and non-Hodgkin variants, originates in lymphocytes and can involve lymph nodes throughout the body. Non-Hodgkin lymphoma is considerably more common and encompasses a wide range of subtypes with varying biological behaviors.
Multiple myeloma affects plasma cells in the bone marrow and is associated with the production of abnormal antibodies. It remains an active area of translational research, particularly in studies involving bone marrow microenvironments and immune cell interactions.
How do treatment approaches differ across cancer types?
Treatment approaches in oncology differ across cancer types based on the tumor’s tissue origin, molecular profile, stage, and biological behavior. The main research-relevant modalities include surgery, radiation, chemotherapy, targeted therapy, immunotherapy, and hormone therapy. In practice, most research programs investigate combinations of these approaches tailored to specific cancer subtypes.
Solid tumors that are localized are often studied in the context of surgical and radiation-based interventions, while systemic therapies are explored for cancers that have spread or cannot be surgically addressed. Blood cancers, which are inherently systemic, are primarily investigated through chemotherapy protocols and bone marrow transplantation research.
The shift toward molecularly targeted approaches has been one of the most significant trends in oncology research. Rather than treating all tumors of a given organ the same way, researchers now investigate how specific mutations or receptor expression predict response to particular agents. This has made molecular profiling a central activity in cancer research laboratories.
Immunotherapy research, including work on checkpoint inhibitors and adoptive cell therapies, has expanded rapidly across multiple cancer types. These approaches are being investigated for lung, skin, bladder, and blood cancers, among others, with laboratory tools for immune cell analysis playing a growing role in supporting this work.
What role does laboratory instrumentation play in cancer research and diagnosis?
Laboratory instrumentation plays a central role in cancer research and diagnosis by enabling the detection, characterization, and study of cancer cells at the molecular, cellular, and tissue levels. Key instrument categories include imaging systems, multimode readers, liquid handling platforms, and flow cytometry tools, all of which support workflows from biomarker discovery to preclinical model development.
In oncology research, the ability to analyze large numbers of samples with precision and reproducibility is critical. Multimode plate readers are used to measure cell viability, proliferation, and apoptosis in drug screening assays. Imaging and microscopy systems allow researchers to visualize tumor cell behavior, migration, and response to experimental conditions at high resolution.
Liquid handling automation reduces variability in sample preparation, which is particularly important in genomic and proteomic workflows where small pipetting errors can significantly affect results. As oncology research increasingly relies on three-dimensional tumor models such as organoids, bioreactor systems designed for organoid culture are becoming more relevant to cancer biology laboratories.
The following instrument types are particularly relevant to oncology research workflows:
- Multimode readers for absorbance, fluorescence, and luminescence-based assays in cell biology and biochemistry
- Imaging and microscopy systems for high-content analysis of tumor cell morphology and behavior
- Liquid handling platforms for automated, reproducible sample preparation in genomic and proteomic workflows
- Bioreactor systems for three-dimensional tumor model culture, including organoid-based cancer research
- Microplate washers and dispensers for high-throughput ELISA and cell-based assay workflows
As cancer research continues to grow in complexity and scale, instrumentation that supports automation and data reproducibility becomes increasingly valuable to research teams working in academic, biotech, and pharmaceutical environments.
How BioSPX supports oncology research in the Benelux
BioSPX provides life science research laboratories in Belgium, the Netherlands, and Luxembourg with the instrumentation needed to support oncology-related workflows. Whether a team is developing cell-based assays, working with three-dimensional tumor models, or scaling up liquid handling processes, BioSPX offers instruments and expertise aligned with current research needs.
- An extensive portfolio covering multimode readers, imaging systems, liquid handling solutions, microplate washers and dispensers, and organoid bioreactor systems
- Product specialists who advise on instrument selection based on experimental setup and research context
- Installation, user training, and maintenance support through a dedicated service department
- ISO 9001-certified operations with offices in the Netherlands and Belgium
Research teams looking to strengthen their oncology workflows with reliable, well-supported instrumentation are welcome to contact BioSPX to discuss their specific requirements.
Frequently Asked Questions
What is the difference between a biomarker and a molecular target in cancer research?
A biomarker is a measurable biological indicator used to detect, monitor, or predict cancer behavior — such as a protein expressed on tumor cells or a circulating nucleic acid in blood. A molecular target, by contrast, is a specific biological molecule that a therapeutic agent is designed to act upon, such as a mutated receptor driving tumor growth. In practice, biomarkers are often used in research assays to identify patients or models that carry a relevant molecular target, making the two concepts closely linked in translational oncology workflows.
How are three-dimensional tumor models like organoids more useful than traditional 2D cell cultures in oncology research?
Organoids and other 3D tumor models better replicate the structural, cellular, and microenvironmental complexity of real tumors compared to flat 2D cell monolayers. This means drug response data generated from 3D models tends to be more predictive of in vivo behavior, reducing the gap between preclinical findings and clinical outcomes. For oncology research teams, this translates to more reliable screening data, particularly when studying tumor invasion, hypoxia, or interactions between cancer cells and surrounding stromal or immune cells.
What assay types are most commonly used to evaluate drug efficacy in solid tumor research?
Cell viability assays, apoptosis assays, and proliferation assays are among the most frequently used tools for evaluating drug efficacy in solid tumor research. These are typically run in multiwell plate formats and measured using multimode plate readers capable of detecting absorbance, fluorescence, or luminescence signals. More advanced workflows may also incorporate high-content imaging to capture morphological changes, or 3D viability assays optimized for spheroid and organoid models.
How do researchers model hematological cancers like leukemia in the laboratory if there is no solid tumor to work with?
Hematological cancers are typically modeled using suspension cell lines derived from patient samples or established leukemia and lymphoma lines grown in liquid culture rather than adherent conditions. Researchers study these cells through flow cytometry, bone marrow co-culture systems, and in vivo xenograft models where cancer cells are introduced into immunocompromised mice. Because these cancers involve complex interactions between malignant cells and the bone marrow or lymph node microenvironment, co-culture platforms and immune cell analysis tools play an important role in recapitulating disease biology in vitro.
What should a laboratory consider when selecting instrumentation for a new oncology research program?
Key considerations include the specific assay types the program will run, the expected sample throughput, and whether workflows require automation to ensure reproducibility at scale. It is also important to evaluate whether the instrument supports the detection modalities needed — for example, fluorescence, luminescence, or brightfield imaging — and whether it is compatible with the plate formats or vessel types used in the lab. Consulting with a product specialist before purchasing can help align instrument capabilities with both current experimental needs and anticipated future workflows.
Can the same laboratory instruments be used across multiple cancer types, or is specialized equipment required for each?
Most core laboratory instruments — such as multimode readers, liquid handling platforms, and imaging systems — are versatile enough to support research across multiple cancer types, since the underlying assay formats are often shared. Specialization tends to occur at the assay or reagent level rather than the instrument level; for example, the same plate reader can run a breast cancer proliferation assay and a leukemia apoptosis assay using different detection channels or reagent kits. This flexibility makes it practical for multi-indication oncology labs to build a core instrument platform that serves a broad range of research programs.
How is automation improving reproducibility in oncology research workflows?
Liquid handling automation reduces the manual pipetting variability that can introduce inconsistencies in sample preparation, particularly in sensitive genomic, proteomic, and cell-based assay workflows. In high-throughput drug screening, for instance, even small volume errors across hundreds of wells can skew dose-response data and compromise conclusions. By standardizing dispensing volumes, timing, and reagent mixing, automated liquid handling platforms help research teams generate more consistent datasets — an increasingly important requirement as oncology studies grow in scale and regulatory scrutiny.
Related Articles
- How can spatially resolved functional data help validate cellular hypotheses?
- Why is proliferation kinetics more informative than a single growth measurement?
- What is the tumor microenvironment and why does it matter in research?
- How do cancer cells develop resistance to treatment over time?
- What does staging mean in oncology?
This content was generated with the help of AI and it may contain mistakes